摘要
目的观察依那普利治疗早期糖尿病肾病的疗效。方法将65例2型糖尿病并早期糖尿病肾病患者随机分为观察组(33例)和对照组(32例),两组均给予常规综合治疗,包括降血糖、利尿、给予必需氨基酸及低盐、优质低蛋白饮食等,观察组在常规治疗基础上加用马来酸依那普利片口服,两组均连续治疗12周。对两组患者监测血压、测定空腹血糖(FPG)、餐后2 h血糖(2 h PBG)、血尿素氮(BUN)、肌酐(Scr)、内生肌酐清除率(Ccr);采用免疫透射比浊法检测尿微量白蛋白(u-ALB),采用微粒子酶免分析法检测β2微球蛋白(β2-MG)。结果治疗后观察组FPG,2 h PBG,Scr,Ccr改善程度明显优于对照组(P<0.05),观察组u-ALB和β2-MG水平显著降低(P<0.01)。结论依那普利能明显降低早期糖尿病肾病患者尿微量白蛋白和β2微球蛋白水平,有助于保护肾功能,延缓糖尿病肾病的进展。
Objective To investigate the effect of enalapril in treating early diabetic nephropathy. Methods Sixty-five patients with type 2 diabetes mellitus（T2DM） complicating early diabetic nephropathy were randomly divided into the observation group（33 cases） and the control group（32 cases）. Two groups were given the routine comprehensive treatment, including lowering blood glucose, essential amino acids, diuretic and low salt, high-quality low- protein diet. The observation group was added Enalapril Maleate Tablet on the base of the conventional therapy. Both the two groups were treated for continuous 12 weeks. Blood pressure was monitored in the two groups, Fasting blood glucose （FPG）, 2 h postprandial blood glucose （2 h PBG）, blood urea nitrogen （BUN）, creatinine （Scr）, endogenous creatinine clearance rate （Ccr） were detected. The immune turbidimetric assay was adopted to determine urine albumin（u-ALB） and the microparticle enzyme immunoassay assay was used to detect β2 microglobulin（β2-MG）. Results The improvement degree of FPG, 2 h PBG, Scr and Ccr after treatment in the observation group were significantly superior to the control group（P〈0.05）. The u-ALB and β2-MG levels in the observation group were significantly decreased（ P 〈 0. 05 or P 〈 0.01 ）. Conclusion Enalapril significant-ly decreases the u-ALB and β2-MG levels in early diabetic nephropathy and helps to protect the renal function and delay the progress of diabetic nephropathy.
出处
《中国药业》
CAS
2012年第21期73-75,共3页
China Pharmaceuticals
